These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
286 related items for PubMed ID: 20589368
21. Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. Emkey R. MedGenMed; 2004 Jul 19; 6(3):6. PubMed ID: 15520628 [Abstract] [Full Text] [Related]
22. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women. Lai PS, Chua SS, Chew YY, Chan SP. J Clin Pharm Ther; 2011 Oct 19; 36(5):557-67. PubMed ID: 21916908 [Abstract] [Full Text] [Related]
23. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. Osteoporos Int; 2007 Aug 19; 18(8):1023-31. PubMed ID: 17308956 [Abstract] [Full Text] [Related]
24. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Ringe JD, Möller G. Rheumatol Int; 2009 Dec 19; 30(2):213-21. PubMed ID: 19430791 [Abstract] [Full Text] [Related]
25. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Ettinger MP, Gallagher R, MacCosbe PE. Endocr Pract; 2006 Dec 19; 12(5):522-8. PubMed ID: 17002926 [Abstract] [Full Text] [Related]
26. Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women. Pasion EG, Sivananthan SK, Kung AW, Chen SH, Chen YJ, Mirasol R, Tay BK, Shah GA, Khan MA, Tam F, Hall BJ, Thiebaud D. J Bone Miner Metab; 2007 Dec 19; 25(2):105-13. PubMed ID: 17323180 [Abstract] [Full Text] [Related]
27. Adherence to Daily, Weekly, and Monthly Dosing Regimens of Bisphosphonates for Osteoporosis Treatment in Postmenopausal Women in Japan: A Retrospective Study Using Claims Data. Kosaka Y, Sugiyama T, Hara K, Kobayashi Y. Tohoku J Exp Med; 2021 Oct 19; 255(2):147-155. PubMed ID: 34690222 [Abstract] [Full Text] [Related]
34. A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women. Yates J. Osteoporos Int; 2013 Jan 19; 24(1):253-62. PubMed ID: 23100120 [Abstract] [Full Text] [Related]
35. Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis. Chapurlat RD. Treat Endocrinol; 2005 Jan 19; 4(2):115-25. PubMed ID: 15783248 [Abstract] [Full Text] [Related]
40. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. Downey TW, Foltz SH, Boccuzzi SJ, Omar MA, Kahler KH. South Med J; 2006 Jun 19; 99(6):570-5. PubMed ID: 16800411 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]